Literature DB >> 25186430

11C-Choline PET/pathology image coregistration in primary localized prostate cancer.

Anca-Ligia Grosu1, Gregor Weirich, Christina Wendl, Vesna Prokic, Simon Kirste, Hans Geinitz, Michael Souvatzoglou, Juergen E Gschwend, Markus Schwaiger, Michael Molls, Wolfgang A Weber, Uwe Treiber, Bernd Joachim Krause.   

Abstract

PURPOSE: The aim of this study was to develop a methodology for the comparison of pathology specimens after prostatectomy (post-S) with PET images obtained before surgery (pre-S). This method was used to evaluate the merit of (11)C-choline PET/CT for delineation of gross tumour volume (GTV) in prostate cancer (PC).
METHODS: In 28 PC patients, (11)C-choline PET/CT was performed before surgery. PET/CT data were coregistered with the pathology specimens. GTV on PET images (GTV-PET) was outlined automatically and corrected manually. Tumour volume in the prostate (TVP) was delineated manually on the pathology specimens. Based on the coregistered PET/pathology images, the following parameters were assessed: SUVmax and SUVmean in the tumoral and nontumoral prostate (NP), GTV-PET (millilitres) and TVP (millilitres).
RESULTS: PET/pathology image coregistration was satisfactory. Mean SUVmax in the TVP was lower than in the NP: 5.0 and 5.5, respectively (p = 0.093). Considering the entire prostate, SUVmax was located in the TVP in two patients, in the TVP and NP in 12 patients and exclusively in NP in 14 patients. Partial overlap the TVP and GTV-PET was seen in 71% of patients, and complete overlap in 4%.
CONCLUSION: PET/pathology image coregistration can be used for evaluation of different imaging modalities. (11)C-Choline PET failed to distinguish tumour from nontumour tissue.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186430     DOI: 10.1007/s00259-014-2861-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  15 in total

1.  The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.

Authors:  Michael Souvatzoglou; Gregor Weirich; Sarah Schwarzenboeck; Tobias Maurer; Tibor Schuster; Ralph Alexander Bundschuh; Matthias Eiber; Ken Herrmann; Hubert Kuebler; Hans Juergen Wester; Heinz Hoefler; Juergen Gschwend; Markus Schwaiger; Uwe Treiber; Bernd Joachim Krause
Journal:  Clin Cancer Res       Date:  2011-04-14       Impact factor: 12.531

2.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

3.  Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy.

Authors:  Joe H Chang; Daryl Lim Joon; Sze Ting Lee; Sylvia J Gong; Andrew M Scott; Ian D Davis; David Clouston; Damien Bolton; Christopher S Hamilton; Vincent Khoo
Journal:  Radiother Oncol       Date:  2011-05-18       Impact factor: 6.280

4.  11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

Authors:  G Martorana; R Schiavina; B Corti; M Farsad; E Salizzoni; E Brunocilla; A Bertaccini; F Manferrari; P Castellucci; S Fanti; R Canini; W F Grigioni; A D'Errico Grigioni
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

5.  Imaging prostate cancer with 11C-choline PET/CT.

Authors:  Sven N Reske; Norbert M Blumstein; Bernd Neumaier; Hans-Werner Gottfried; Frank Finsterbusch; Darius Kocot; Peter Möller; Gerhard Glatting; Sven Perner
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

Review 6.  The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

Authors:  Maria Picchio; Alberto Briganti; Stefano Fanti; Axel Heidenreich; Bernd J Krause; Cristina Messa; Francesco Montorsi; Sven N Reske; George N Thalmann
Journal:  Eur Urol       Date:  2010-09-15       Impact factor: 20.096

7.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

8.  Visualization of prostate cancer with 11C-choline positron emission tomography.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2002-07       Impact factor: 20.096

9.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

10.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.

Authors:  Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

View more
  9 in total

1.  11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml.

Authors:  Giampiero Giovacchini; Priscilla Guglielmo; Paola Mapelli; Elena Incerti; Ana Maria Samanes Gajate; Elisabetta Giovannini; Mattia Riondato; Alberto Briganti; Luigi Gianolli; Andrea Ciarmiello; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-10       Impact factor: 9.236

Review 2.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

3.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

4.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.

Authors:  Constantinos Zamboglou; Vanessa Drendel; Cordula A Jilg; Hans C Rischke; Teresa I Beck; Wolfgang Schultze-Seemann; Tobias Krauss; Michael Mix; Florian Schiller; Ulrich Wetterauer; Martin Werner; Mathias Langer; Michael Bock; Philipp T Meyer; Anca L Grosu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

5.  Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation.

Authors:  F Schiller; T Fechter; C Zamboglou; A Chirindel; N Salman; C A Jilg; V Drendel; M Werner; P T Meyer; A-L Grosu; M Mix
Journal:  EJNMMI Phys       Date:  2017-08-17

Review 6.  Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.

Authors:  Constantinos Zamboglou; Matthias Eiber; Thomas R Fassbender; Matthias Eder; Simon Kirste; Michael Bock; Oliver Schilling; Kathrin Reichel; Uulke A van der Heide; Anca L Grosu
Journal:  Phys Imaging Radiat Oncol       Date:  2018-11-05

7.  Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.

Authors:  Constantinos Zamboglou; Hans-Christian Rischke; Philipp Tobias Meyer; Sven Knobe; Natalja Volgeova-Neher; Michael Kollefrath; Cordula Annette Jilg; Anca Ligia Grosu; Dimos Baltas; Malte Kroenig
Journal:  J Contemp Brachytherapy       Date:  2016-07-01

8.  (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.

Authors:  Constantinos Zamboglou; Florian Schiller; Tobias Fechter; Gesche Wieser; Cordula Annette Jilg; Alin Chirindel; Nasr Salman; Vanessa Drendel; Martin Werner; Michael Mix; Philipp Tobias Meyer; Anca Ligia Grosu
Journal:  Theranostics       Date:  2016-06-18       Impact factor: 11.556

9.  The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.

Authors:  Lucia Zanoni; Riccardo Mei; Lorenzo Bianchi; Francesca Giunchi; Lorenzo Maltoni; Cristian Vincenzo Pultrone; Cristina Nanni; Irene Bossert; Antonella Matti; Riccardo Schiavina; Michelangelo Fiorentino; Cristina Fonti; Filippo Lodi; Antonietta D'Errico; Eugenio Brunocilla; Stefano Fanti
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.